Evidence map›Paper›PMID 31805674›Full record

ArticleJournal of clinical medicine2019

Preventive Effect of Cardiotrophin-1 Administration before DSS-Induced Ulcerative Colitis in Mice.

Ana I Sánchez-Garrido, Vanessa Prieto-Vicente, Víctor Blanco-Gozalo, Miguel Arévalo, Yaremi Quiros, Daniel López-Montañés, Francisco J López-Hernández, Antonio Rodríguez-Pérez, José M López-Novoa

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Evidence-based complementary and alternative medicine : eCAM · 2022
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ana I Sánchez-GarridoDepartment of Gastroenterology, University Hospital of Salamanca, 37007 Salamanca, Spain.
Vanessa Prieto-VicenteDepartment of Gastroenterology, University Hospital of Salamanca, 37007 Salamanca, Spain.
Víctor Blanco-GozaloBio-inRen S.L. Faculty of Medicine, Campus Miguel de Unamuno, 37007 Salamanca, Spain.
Miguel ArévaloInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain..
Yaremi QuirosBio-inRen S.L. Faculty of Medicine, Campus Miguel de Unamuno, 37007 Salamanca, Spain.
Daniel López-MontañésInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain..
Francisco J López-HernándezInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain..
Antonio Rodríguez-PérezDepartment of Gastroenterology, University Hospital of Salamanca, 37007 Salamanca, Spain.
José M López-NovoaInstitute for Biomedical Research of Salamanca (IBSAL), 37007 Salamanca, Spain..ORCID 0000-0002-6211-7269
Universidad de Salamanca · ESInstituto de Investigación Biomédica de Salamanca · ES

Funding

Consejería de Educación, Junta de Castilla y León GR-100Consejería de Educación, Junta de Castilla y León GRS1217/A/15Digna Biotech Digna-5/2017Fundacion Salmantina para el estudio de las Enfermedades Hepaticas (Salamanca Fundation for Liver diseases Study) FSEEH/3/2017: FSEEH/1/2018
6 · The paper itself

Abstract

Ulcerative colitis is a relatively frequent, chronic disease that impacts significantly the patient's quality of life. Although many therapeutic options are available, additional approaches are needed because many patients either do not respond to current therapies or show significant side effects. Cardiotrophin-1 (CT-1) is a cytokine with potent cytoprotective, anti-inflammatory, and antiapoptotic properties. The purpose of this study was to assess if the administration of CT-1 could reduce colon damage in mice with experimental colitis was induced with 5% dextran sulfate sodium (DSS) in the drinking water. Half of the mice received an i.v. dose of CT-1 (200 µg/kg) 2 h before and 2 and 4 days after DSS administration. Animals were followed during 7 days after DSS administration. The severity of colitis was measured by standard scores. Colon damage was assessed by histology and immunohistochemistry. Inflammatory mediators were measured by Western blot and PCR. CT-1 administration to DSS-treated mice ameliorated both the clinical course (disease activity index), histological damage, inflammation (colon expression of TNF-α, IL-17, IL-10, INF IFN-γ, and iNOS), and apoptosis. Our results suggest that CT-1 administration before induction of colitis improves the clinical course, tissue damage, and inflammation in DSS-induced colitis in mice.

Indexed as

apoptosiscardiotrophin-1coloninflammation

Identifiers

PMID31805674
PMCPMC6947259
OpenAlexW2979879938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.